Primmune Therapeutics Appoints Chief Medical Officer and Executive Board Chair; Establishes Melanoma Clinical Study Advisory Board
Leadership additions strengthen clinical excellence and governance as the company enters its next phase of growth Primmune Therapeutics, Inc., a biotech company harnessing the power of the innate immune system, today announced the appointment of Andrew Sharabi, M.D., Ph.D., as Chief Medical Officer and Chris Krueger, J.D., as Executive Chairman of its Board of Directors. […]
Bioqube Ventures strengthens leadership team with the appointment of Tessa Ceyssens as Chief Operating Officer
Bioqube Ventures, an emerging life sciences investment firm, today announces the appointment of Tessa Ceyssens as Chief Operating Officer (COO). With her arrival, Bioqube Ventures adds a seasoned senior executive to its leadership team to support the continued build-out and professionalisation of the organisation in a rapidly evolving and dynamic market. Tessa joins Bioqube Ventures […]
Primmune Therapeutics Announces Additional Close of Series B Financing
Today, Primmune Therapeutics, a biotech company harnessing the power of the innate immune system, announced an additional close of its Series B financing round for a total of $8.6 million with participation from Bioqube Ventures, Oberland Capital and Samsara Biocapital. This close brings the total Series B raise to $23.3 million. These funds will be […]
SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress
Charles “Chip” Romp and Tom Heyman join SynOx’s Board, bringing deep launch, lifecycle, and corporate development expertise as the company advances its next-generation therapy emactuzumab toward key regulatory and commercial milestones DUBLIN, IRELAND, OXFORD, UK, and PHILADELPHIA, PA — October 21, 2025 SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial […]
CatalYm Presents Long-Term Phase 1/2a Data Confirming Sustained Responses with Visugromab in CPI-Refractory Tumors at ESMO 2025
Median duration of response exceeded 32 months in non-squamous non-small cell lung cancer (nsqNSCLC), 28 months in urothelial cancer (UC) and 19 months in hepatocellular carcinoma (HCC), with more than half of responses ongoing at the data cut-off Majority of responders experienced deeper and longer-lasting responses when compared to prior anti-PD-1/PD-(L)1 treatment GDF-15 blockade re-sensitized […]
CatalYm Presents Phase 2 Data in Neoadjuvant Bladder Cancer Demonstrating Substantial Increase of Anti-Tumor Activity for Visugromab in Combination with PD-1 Inhibitor at ESMO
Visugromab combined with PD-1 inhibitor, nivolumab, more than quadrupled the rate of pathological Complete Response (pCR; 33.3% vs. 7.1%) and substantially increased Major Pathologic Response (MPR; 66.7% vs. 21.4%) rate compared to nivolumab alone Combination achieved a fourfold increase in radiologic Objective Response Rate (rORR) (60% vs. 14.3%) Visugromab + nivolumab showed good tolerability in […]
Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC
Designation supported by results from multiple dose cohorts from the Phase 1/1b trial of ficerafusp alfa in 1L HPV-negative R/M HNSCC BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) — Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that the U.S. Food and […]
CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as First-Line Treatment in Metastatic Non-squamous NSCLC
Munich, Germany and San Francisco, USA, September 30, 2025 – CatalYm today announced that the first patient has been dosed in the randomized Phase 2b GDFATHER-NSCLC-01 trial (NCT07098988). The trial investigates the efficacy and safety of the company’s anti-GDF-15 antibody visugromab, in combination with standard-of-care chemoimmunotherapy, compared to placebo plus chemoimmunotherapy, as a first-line treatment […]
CatalYm to Present New Data Demonstrating GDF-15 Blockade Enhances Efficacy of Antibody-Drug Conjugates at AACR 2025
Preclinical in vitro and in vivo data show enhanced anti-tumor activity when combining visugromab, a GDF-15-neutralizing antibody candidate, with approved antibody-drug-conjugate (ADC) treatment GDF-15 blockade enhances ADC activity, immune cell infiltration, and activation in the tumor Findings support continued investigation of GDF-15 neutralization as a potential strategy to overcome cancer therapy resistance for a variety of treatment modalities CatalYm today […]
Bioqube Ventures Appoints Tom Heyman as Executive Partner
Bioqube Ventures, an emerging life sciences investment firm, is pleased to announce the appointment of Tom Heyman as Executive Partner, joining the firm’s leadership team. Tom Heyman is a seasoned pharma executive with more than 40 years of experience in general management, business development, and equity investments. He spent his entire career at Johnson & Johnson and […]